<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005131.pub2" GROUP_ID="RENAL" ID="639704052411175243" MERGED_FROM="" MODIFIED="2008-05-14 00:38:03 +0200" MODIFIED_BY="Narelle Willis" REVIEW_NO="095" REVMAN_SUB_VERSION="5.0.8" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2008-05-14 00:38:03 +0200" MODIFIED_BY="Narelle Willis">
<TITLE>Oestrogens for preventing recurrent urinary tract infection in postmenopausal women</TITLE>
<CONTACT MODIFIED="2008-05-14 00:38:03 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="18173" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carla</FIRST_NAME><LAST_NAME>Perrotta</LAST_NAME><EMAIL_1>carla.perrotta@ucd.ie </EMAIL_1><EMAIL_2>carlaperrotta@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Woodview House</DEPARTMENT><ORGANISATION>UCD School of Public Health and Population Sciences</ORGANISATION><ADDRESS_2>Belfield</ADDRESS_2><CITY>Dublin</CITY><ZIP>4</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 716 3180</PHONE_1><FAX_1>+353 1 716 7407</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-05-14 00:38:03 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="18173" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carla</FIRST_NAME><LAST_NAME>Perrotta</LAST_NAME><EMAIL_1>carla.perrotta@ucd.ie </EMAIL_1><EMAIL_2>carlaperrotta@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Woodview House</DEPARTMENT><ORGANISATION>UCD School of Public Health and Population Sciences</ORGANISATION><ADDRESS_2>Belfield</ADDRESS_2><CITY>Dublin</CITY><ZIP>4</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 716 3180</PHONE_1><FAX_1>+353 1 716 7407</FAX_1></ADDRESS></PERSON><PERSON ID="57CAE26E82E26AA2000F11BC0A5CFB0C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mireya</FIRST_NAME><LAST_NAME>Aznar</LAST_NAME><POSITION>Staff Physician</POSITION><EMAIL_1>jgoland@intramed.net.ar</EMAIL_1><ADDRESS><DEPARTMENT>Programa de Medicina Interna General (PMIG)</DEPARTMENT><ORGANISATION>Hospital de Clínicas, Universidad de Buenos Aires</ORGANISATION><ADDRESS_1>Av. Córdoba 2351, PB</ADDRESS_1><CITY>Ciudad de Buenos Aires</CITY><ZIP>1122</ZIP><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 11 59508474</PHONE_1></ADDRESS></PERSON><PERSON ID="C21FD39282E26AA200F0756DB3E6E165" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Raul</FIRST_NAME><LAST_NAME>Mejia</LAST_NAME><EMAIL_1>raulmejia@ciudad.com.ar</EMAIL_1><ADDRESS><DEPARTMENT>Programa de Medicina Interna General (PMIG)</DEPARTMENT><ORGANISATION>Hospital de Clínicas, Universidad de Buenos Aires</ORGANISATION><ADDRESS_1>Av. Córdoba 2351, PB</ADDRESS_1><CITY>Ciudad de Buenos Aires</CITY><ZIP>1122</ZIP><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 11 48153912</PHONE_1></ADDRESS></PERSON><PERSON ID="18394" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xavier</FIRST_NAME><LAST_NAME>Albert</LAST_NAME><POSITION>Family Physician</POSITION><EMAIL_1>albert_xav@gva.es</EMAIL_1><ADDRESS><DEPARTMENT>Health Center of Montcada. Department 6</DEPARTMENT><ORGANISATION>Valencian Agency of Health</ORGANISATION><ADDRESS_1>Av. Mediterraneo s/n</ADDRESS_1><ADDRESS_2>Montcada</ADDRESS_2><CITY>Valencia</CITY><ZIP>46113</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 96 1394367</PHONE_1><FAX_1>+34 96 1300173</FAX_1></ADDRESS></PERSON><PERSON ID="C21FD52982E26AA200F0756D73740F76" ROLE="AUTHOR"><FIRST_NAME>Cheen Werne</FIRST_NAME><LAST_NAME>Ng</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>wernelle@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>Penang Medical College</ORGANISATION><CITY>Penang</CITY><COUNTRY CODE="MY">Malaysia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-12 16:05:46 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="31" MONTH="1" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="2" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="12" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="12" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-12 16:06:09 +1000" MODIFIED_BY="Narelle S Willis"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Health Research Board</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Iberoamerican Cochrane Center, Barcelona</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>UCD School of Public Health and Population Sciences</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-14 08:35:01 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2008-05-12 16:06:29 +1000" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2008-05-12 16:06:29 +1000" MODIFIED_BY="Narelle S Willis">Oestrogens for preventing recurrent urinary tract infection in postmenopausal women</TITLE>
<SUMMARY_BODY>
<P>Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. In postmenopausal women the prevalence rate for having one episode of UTI in a given year varies from 8% to 10%. This increased risk is associated with a decrease in oestrogen levels. The use of oestrogens (orally or vaginally) has been proposed as a preventive strategy. This review identified nine studies (3345 women) treated with oestrogens versus placebo, no treatment or antibiotics. Vaginal oestrogens reduced the number of UTIs when compared to placebo. All studies reported adverse events for the oestrogen treatment groups. These included breast tenderness, vaginal bleeding or spotting, vaginal discharge, vaginal irritation, burning and itching.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-12 16:09:12 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND>
<P>Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. The main factors associated with RUTI in postmenopausal women are vesical prolapse, cystocoele, post-voidal residue and urinary incontinence, all associated with a decrease in oestrogen. The use of oestrogens to prevent RUTI has been proposed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the efficacy and safety of oral or vaginal oestrogens for preventing RUTI in postmenopausal women.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1950), EMBASE (from 1980), reference lists of articles without language restriction.<BR/>
<I>Date of last search: February 2007.</I>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) in which postmenopausal women (more than 12 months since last menstrual period) diagnosed with RUTI received any type of oestrogen (oral , vaginal) versus placebo or any other intervention were included. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-12 16:09:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Authors extracted data and assessed quality. Statistical analyses were performed using the random effects model and the results expressed as risk ratios (RR) for dichotomous outcomes or mean difference (MD) for continuous data with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Nine studies (3345 women) were included. Oral oestrogens did not reduce UTI compared to placebo (4 studies, 2798 women: RR 1.08, 95% CI 0.88 to 1.33). Vaginal oestrogens versus placebo reduced the number of women with UTIs in two small studies using different application methods. The RR for one was 0.25 (95% CI 0.13 to 0.50) and 0.64 (95% CI 0.47 to 0.86) in the second. Two studies compared oral antibiotics versus vaginal oestrogens (cream (1), pessaries (1)). There was very significant heterogeneity and the results could not be pooled. Vaginal cream reduced the proportion of UTIs compared to antibiotics in one study and in the second study antibiotics were superior to vaginal pessaries. Adverse events for vaginal oestrogens were breast tenderness, vaginal bleeding or spotting, nonphysiologic discharge, vaginal irritation, burning and itching.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Based on only two studies comparing vaginal oestrogens to placebo, vaginal oestrogens reduced the number of UTIs in postmenopausal women with RUTI, however this varied according to the type of oestrogen used and the treatment duration. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-14 08:35:01 +1000" MODIFIED_BY="Narelle S Willis">
<BACKGROUND>
<P>Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. In postmenopausal women the prevalence rate for having one episode of UTI in a given year varies from 8% to 10%. Of those women who have an episode, 5% will experience a recurrence within the year (<LINK REF="REF-Brown-1999" TYPE="REFERENCE">Brown 1999</LINK>; <LINK REF="REF-Foxman-2000" TYPE="REFERENCE">Foxman 2000</LINK>).</P>
<P>In premenopausal women the main risk factors associated with RUTI are frequency of sexual intercourse, the use of spermicides, the age at first UTI (less than 15 years of age indicates a greater risk of RUTI) and a history of UTI in the mother. After menopause the main risk factors are vaginal prolapse, cystocoele, post-voidal residue, changes in vaginal flora, and urinary incontinence (<LINK REF="REF-Foxman-2000" TYPE="REFERENCE">Foxman 2000</LINK>; <LINK REF="REF-Raz-2000" TYPE="REFERENCE">Raz 2000</LINK>). Weaker associations have been found with non-secretor status and a history of UTI before menopause. The association of RUTI with sexual habits, such as frequency of sexual intercourse and the use of spermicides is not as positive as in younger women. No association were found in a study by <LINK REF="REF-Foxman-2001" TYPE="REFERENCE">Foxman 2001</LINK> and in another case controlled study, sexually active women had an odds ratio (OR) of 1.42 (95% CI 1.07 to 1.87) of having RUTIs over non-sexually active women (<LINK REF="REF-Hu-2004" TYPE="REFERENCE">Hu 2004</LINK>).</P>
<P>Several approaches have been proposed for the prevention of RUTI. A Cochrane systematic review showed that antibiotics are effective in reducing the number or recurrences. However, adverse events were common and compliance with treatment varied (<LINK REF="REF-Albert-2004" TYPE="REFERENCE">Albert 2004</LINK>). Cranberry juice or cranberry pills has some effect as a preventive strategy (<LINK REF="REF-Jepson-2004" TYPE="REFERENCE">Jepson 2004</LINK>).</P>
<P>During the last few decades there has been an increasing interest in the treatment with local or oral oestrogens for the prevention of UTI and urinary symptoms in postmenopausal women. Basic research has demonstrated that oestrogens receptors are present in the vagina, urethra, the trigone of the bladder and pelvic floor musculature. It is believed that they play a crucial role in the continence mechanism (<LINK REF="REF-Iosif-1981" TYPE="REFERENCE">Iosif 1981</LINK>; <LINK REF="REF-Robinson-2003" TYPE="REFERENCE">Robinson 2003</LINK>). </P>
<P>Vaginal flora changes with the reduction of local and circulating estrogens during menopause. Vaginal pH rises after and vaginal Lactobacillus decrease, allowing gram negative bacteria to grow and act as uropathogen. A Cochrane systematic review (<LINK REF="REF-Suckling-2006" TYPE="REFERENCE">Suckling 2006</LINK>) concluded that vaginal estrogens improve vaginal atrophia and increase vaginal <I>Lactobacillus</I>. A Cochrane systematic review by <LINK REF="REF-Moehrer-2004" TYPE="REFERENCE">Moehrer 2004</LINK> reported that oestrogens are effective in the subjective impression of cure in women with urinary incontinence, and that increase as well the presence of <I>Lactobacillus</I> and vaginal pH decrease. Given this evidence oestrogens have been proposed as a strategy for the prevention of UTI in postmenopausal women. Several methods of administration have been tested: oral, vaginal cream, vaginal tablets, vaginal ring and vaginal pessaries.</P>
<P>However some controversy surrounds the use of oestrogens in RUTI. While it appears that vaginal oestrogens decrease UTI occurrence, oral oestrogens apparently do not have this effect. In addition, there is concern in relation to its long term use and the adverse events associated with them. There is also some evidence suggesting oral antibiotics have a higher efficacy as a preventing strategy for RUTI than local oestrogen use (<LINK REF="REF-Raz-2001" TYPE="REFERENCE">Raz 2001</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the efficacy of oestrogens (oral or vaginal) in decreasing the rate of RUTI in postmenopausal women and their safety (in terms of systemic or local adverse events such as allergic reactions or local irritation).</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included randomised controlled trials (RCTs) and quasi randomised-RCTs (in which allocation to treatment was obtained by alternation, medical record numbers, date of birth or other predictable methods). </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All postmenopausal women (more than 12 months since last menstrual period) with RUTIs (defined as three UTI episodes in the last 12 months or two episodes in the last six months) where at least one UTI outcome was assessed. There were no exclusions based on other underlying disease or urinary tract abnormality.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-12 16:06:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Oral oestrogens (with or without progestogens), or vaginal oestrogens (delivered by cream, vaginal ring, vaginal pessaries, vaginal tables or any other formulation) given at any dose or any length of treatment used as a preventive strategy for the reduction of RUTI versus:<BR/>
</P>
<UL>
<LI>Placebo.</LI>
<LI>Another type of oestrogen delivery (e.g. oral versus local, cream versus vaginal ring, vaginal ring versus vaginal pessaries).</LI>
<LI>Another preventive strategy (e.g. antibiotic, cranberry juice).</LI>
<LI>No treatment.</LI>
</UL>
<P>We excluded those studies that only included assessment of vaginal atrophia as this has been covered in another Cochrane review (<LINK REF="REF-Suckling-2006" TYPE="REFERENCE">Suckling 2006</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-05-12 16:07:12 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Women with RUTIs at the end<B> </B>of active treatment period.</LI>
<LI>UTIs at the end active treatment period.</LI>
<LI>Time until recurrence.</LI>
<LI>Number of urinary infections/person/year.</LI>
<LI>Number of asymptomatic women at the end of the study.</LI>
<LI>Number of relapsing after the end of the study.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Proportion of women <I>Lactobacillus</I> positive.</LI>
<LI>Vaginal pH at the end of the active treatment period.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Proportion of severe adverse events (resulting in the cessation of treatment).</LI>
<LI>Proportion of referred adverse events.</LI>
<LI>Endometrial thickness at the end of the active treatment period.</LI>
<LI>Proportion of women with vaginal bleeding or spotting.</LI>
<LI>Proportion of women with breast tenderness.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-12 16:29:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the following electronic bibliographic databases (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> - <I>Electronic search strategies)</I>
<BR/>
</P>
<UL>
<LI>The Cochrane Renal Group's specialised register and the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(issue 1, 2007). CENTRAL and the Renal Groups Specialised Register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<LINK REF="REF-Master-List-2007" TYPE="REFERENCE">Master List 2007</LINK>). Therefore we did not specifically search conference proceedings.</LI>
<LI>MEDLINE (1950 to February 2007) using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) with a specific search strategy developed with input from the Cochrane Renal Group Trial Search Coordinators.</LI>
<LI>EMBASE (1980 to February 2007) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>) together with a specific search strategy developed with input from the Cochrane Renal Group Trial Search Coordinators.</LI>
<LI>Lilacs (1988 to February 2007).</LI>
<LI>Reference list of retrieved articles.</LI>
<LI>Communication with authors for clarification of results and/or methods. We contacted <LINK REF="STD-Kjaergaard-1990" TYPE="STUDY">Kjaergaard 1990</LINK>, but could not reach the investigators from <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>.</LI>
</UL>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-12 16:08:50 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two authors (CP, CW) independently screened the initial search results of all the databases and references lists to identify citations relevant to our review. Once identified the abstracts were checked and full text articles obtained when inclusion criteria were met.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Each RCT was evaluated by two authors (CW, MA) and a third author (CP) resolved discrepancies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study.</LI>
<LI>Unclear (B): Randomisation stated but no information on method used is available.</LI>
<LI>Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Blinding of investigators: Yes/no/not stated.</LI>
<LI>Blinding of participants: Yes/no/not stated.</LI>
<LI>Blinding of outcome assessor: Yes/no/not stated.</LI>
<LI>Blinding of data analysis: Yes/no/not stated.</LI>
</UL>
<P>The above are considered not blinded if the treatment group can be identified in &gt; 20% of participants because of the side effects of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analysis</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: Not stated but confirmed on study assessment.</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment. (Women who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation).</LI>
<LI>No: Stated but not confirmed upon study assessment.</LI>
<LI>Not stated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness of follow-up</HEADING>
<P>Number of participants with data/number of participants randomised, expressed as a percentage overall and in each intervention group.</P>
<P>We evaluated outcome definitions (how the authors defined clinical and microbiological recurrences) and the ways in which adverse events were recalled. Discrepancies in those definitions and assessments were taken into consideration while doing the analysis especially if heterogeneity was identified.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Data was extracted using a data extraction form (CW, MA) and then entered into RevMan. CP checked the original papers for discrepancies. Dichotomous outcomes were analysed as risk ratio (RR) and 95% confidence interval (CI). The time until recurrence was intended to be done using Kaplan-Meier method. However, because we could not contact the authors to obtain individual data from each of the studies, we have reported the results from each study individually. Continuous variables were analysed using mean differences (MD) and 95% CI. We used random effects model to assess overall treatment effects. Heterogeneity was analysed using a chi squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and the I²<SUP> </SUP>test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). ). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. When heterogeneity was found we did subgroup analysis according to the intervention, study design (RCT and quasi-RCTs) and blinding.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-12 16:10:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>We identified 17 potential studies from the search strategy. We excluded eight studies ( <LINK REF="STD-Ayton-1996" TYPE="STUDY">Ayton 1996</LINK>; <LINK REF="STD-Brandberg-1987" TYPE="STUDY">Brandberg 1987</LINK>; <LINK REF="STD-Chompootaweep-1998" TYPE="STUDY">Chompootaweep 1998</LINK>; <LINK REF="STD-Henriksson-1996" TYPE="STUDY">Henriksson 1996</LINK>; <LINK REF="STD-Marx-2004" TYPE="STUDY">Marx 2004</LINK>; <LINK REF="STD-Molander-1990" TYPE="STUDY">Molander 1990</LINK>; <LINK REF="STD-Notelovitz-1995" TYPE="STUDY">Notelovitz 1995</LINK>; <LINK REF="STD-Orlander-1992" TYPE="STUDY">Orlander 1992</LINK>) because they only reported on vaginal atrophy which has been covered by another Cochrane review ( <LINK REF="REF-Suckling-2006" TYPE="REFERENCE">Suckling 2006</LINK>) or the population did not have to have had a previous UTI. Nine studies (3345 women) met our inclusion criteria (<LINK REF="STD-Brown-2001" TYPE="STUDY">Brown 2001</LINK>; <LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK>; <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>; <LINK REF="STD-Kirkengen-1992" TYPE="STUDY">Kirkengen 1992</LINK>; <LINK REF="STD-Kjaergaard-1990" TYPE="STUDY">Kjaergaard 1990</LINK>; <LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>; <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>; <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) (see table: <I>Characteristics of included studies</I>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<UL>
<LI>Oral oestrogens versus placebo (<LINK REF="STD-Brown-2001" TYPE="STUDY">Brown 2001</LINK>; <LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK>; <LINK REF="STD-Kirkengen-1992" TYPE="STUDY">Kirkengen 1992</LINK>; <LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>).</LI>
<LI>Vaginal oestrogens versus placebo (<LINK REF="STD-Kjaergaard-1990" TYPE="STUDY">Kjaergaard 1990</LINK>; <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>; <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>).</LI>
<LI>Vaginal oestrogens versus antibiotics (<LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reported outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oral oestrogens versus placebo </HEADING>
<UL>
<LI>Proportion of two or more UTIs during first, second, third and forth year of treatment as reported by the participants answering the question: "During the past year, how many times has a doctor told you that you had a urinary tract infection?" (<LINK REF="STD-Brown-2001" TYPE="STUDY">Brown 2001</LINK>).</LI>
<LI>The proportion of women who developed at least one UTI during the study period (<LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK>).</LI>
<LI>The percentage of vaginal superficial cells, vaginal pH, vaginal parabasal cells, bacteriuria and pyuria, and presence of <I>Lactobacillus</I> (<LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>).</LI>
<LI>Proportion of women with two UTIs at the end of treatment period and vaginal pH (<LINK REF="STD-Kirkengen-1992" TYPE="STUDY">Kirkengen 1992</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vaginal oestrogens versus placebo</HEADING>
<UL>
<LI>Women were evaluated once a month for five months to evaluate the number of positive cultures and patient satisfaction (<LINK REF="STD-Kjaergaard-1990" TYPE="STUDY">Kjaergaard 1990</LINK>).</LI>
<LI>Proportion of women with RUTI and proportion of women remaining free of UTI, vaginal atrophy and vaginal pH (<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>).</LI>
<LI>Incidence of UTI, proportion of women remaining free of UTI and number of episodes of UTI/patient/year, presence of <I>Lactobacillus</I> and vaginal pH (<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vaginal oestrogens versus antibiotics</HEADING>
<UL>
<LI>Number of UTI episodes/patient/year, the proportion of women who remained free of UTI, percentage of superficial cells and the presence of <I>Lactobacillus</I> (<LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK>).</LI>
<LI>Proportion of women with UTI at the end of the study period, adverse events and vaginal atrophy (<LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-12 16:10:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Overall, the quality of the included studies were good.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>One study had adequate allocation concealment (<LINK REF="STD-Brown-2001" TYPE="STUDY">Brown 2001</LINK>) and the rest were unclear. In the study by <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> it was not clear why the two groups were unbalanced (oestriol group n = 30; antibiotic group n = 15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Eight studies were 'double blind'. <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> had a no treatment control group and the women and investigators were therefore not blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat</HEADING>
<P>All studies analysed by intention-to-treat. <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> also analysed 'per-protocol'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<UL>
<LI>
<LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK>: Twenty-two women were unable to complete the study. Reasons for early discontinuation in the oestriol group (n = 13) were major protocol violation (n = 4); hospital admission (n = 2); bleeding (n = 2); cerebrovascular accident (n = 2); poor compliance; adverse experiences; and depression. Early discontinuation reasons in the placebo group (n = 9) included femur fracture (n = 2); poor compliance; major protocol violation; septicaemia; cerebrovascular accident; left arm paresis; adverse experiences and general decline in health.</LI>
<LI>
<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>: Five subjects (9%) withdrew from the ring group and 1 subject (2%) withdrew from the control group before completion of the 36-week study period or before first recurrence (control group).</LI>
<LI>
<LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>: Three (9%) dropped out before the 3-month examination (two active, one placebo), leaving 29 subjects who had 3-month measures (13 active and 16 placebo; 91% of those enrolled). An additional eight (25%) dropped out before the 6-month examination (four active, four placebo), leaving 21 subjects who had 6-month measures (nine active and 12 placebo; 66% of those enrolled). Reasons for dropping out were primarily various acute illnesses (which resulted in two deaths).</LI>
<LI>
<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>: reasons for early withdrawal from the study: side effects in 10 women in the oestriol group and 4 in the placebo group; lack of compliance with follow-up in 3 and 5 women, respectively; death due to myocardial infarction in 1 oestriol-treated patient; and failure to respond to topical prophylaxis necessitating systemic antimicrobial prophylaxis for recurrent infections in 10 women in the placebo group.</LI>
<LI>
<LINK REF="REF-Raz-2001" TYPE="REFERENCE">Raz 2001</LINK>: Twenty-seven women in the oestriol group and 23 in the NM group dropped out. Reasons for dropout included adverse events (9 women in the oestriol group and 14 in the NM group), lack of compliance with the treatment regimen (13 and 6, respectively), and intermittent illness (3 and 2, respectively).</LI>
</UL>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-12 16:22:49 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Oral oestrogens versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of women with UTI at the end of the treatment period</HEADING>
<P>Four studies assessed this outcome (<LINK REF="STD-Brown-2001" TYPE="STUDY">Brown 2001</LINK>; <LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK>; <LINK REF="STD-Kirkengen-1992" TYPE="STUDY">Kirkengen 1992</LINK>; <LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>). There was no significant difference in the number of women with UTI at the end of the treatment period between oral oestrogens and placebo (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (4 studies, 2798 women): RR 1.08, 95% CI 0.88 to 1.33; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vaginal pH</HEADING>
<P>Two studies reported the change in vaginal pH (<LINK REF="STD-Kirkengen-1992" TYPE="STUDY">Kirkengen 1992</LINK>; <LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>). There was a significant decrease in vaginal pH with the oral oestrogens (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (2 studies, 62 women): MD -1.00, 95% CI -1.43 to -0.57; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of women Lactobacillus positive</HEADING>
<P>One study (<LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK>) reported this outcome. There was no significant difference between the two groups in the number of women who were <I>Lactobacillus</I> positive (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (1 study, 32 women): RR 10.13, 95% CI 0.59 to 173.83).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All adverse events</HEADING>
<P>Two studies reported adverse events that occurred during the treatment period. <LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK> reported breast tenderness and mild vaginal bleeding, and <LINK REF="STD-Ouslander-2001" TYPE="STUDY">Ouslander 2001</LINK> reported vaginal spotting and mild breast discomfort (present in minority, however number not reported). There were significantly less adverse events in the placebo group (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (2 studies, 104 women): RR 5.11, 95% CI 1.39 to 18.76; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes reported </HEADING>
<P>
<LINK REF="STD-Cardozo-1998" TYPE="STUDY">Cardozo 1998</LINK> reported 34% women free of infection in the oestriol group at the end of the study period (12 months) versus 44% in the placebo group. The results were not statistical significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vaginal oestrogens versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of infection at the end of the treatment period</HEADING>
<P>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>
</P>
<P>Two studies (<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>; <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>) reported this outcome. We did not pool these studies as there was significant heterogeneity. The heterogeneity could be explained by the type of application method used. <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> compared topically applied intravaginal oestriol cream oestrogens to placebo cream while <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> compared releasing silicone vaginal ring (Estring) (2 mg oestriol) with no treatment control group. The RR for <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>, was 0.25 (95% CI 0.13 to 0.50) and in <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>, the RR was 0.64 (95% CI 0.47 to 0.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vaginal pH</HEADING>
<P>
<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> reported a significant decrease in pH with vaginal oestrogens (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (93 women): MD -2.50, 95% CI -3.16 to -1.84).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of women Lactobacillus positive</HEADING>
<P>
<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> reported significantly more women were <I>Lactobacillus</I> positive in the vaginal oestrogen group (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (93 women): RR 38.82, 95% CI 2.42 to 621.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All adverse events</HEADING>
<P>The adverse events included vaginal bleeding and nonphysiologic discharge (<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>), and vaginal irritation, burning, or itching (<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>). There was no significant difference in adverse events between the two groups (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (201 women): RR 4.72, 95% CI 0.67 to 33.53; I² = 67.5%), however there was moderate heterogeneity. The control group in <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> received no treatment and the control group in <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> received a placebo cream.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes</HEADING>
<UL>
<LI>
<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> reported that after 9 months the 45% of participants were free of UTIs in the oestrogen group and approximately 20% in the control group (P &lt; 0.008). In <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>, the intervention group had a cumulative likelihood of remaining disease free of 0.95 and the placebo group 0.30 (P &lt; 0.001 log rank test).</LI>
<LI>
<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> reported the mean number of days of antibiotic use. The oestrogen group received antibiotics for 6.9 days (± 1.1 SD) and the placebo group 32.0 days (± 7.8) (P &lt; 0.001).</LI>
<LI>
<LINK REF="STD-Kjaergaard-1990" TYPE="STUDY">Kjaergaard 1990</LINK> reported a median of 1.5 UTIs in the oestrogen group and 1 in the control group (range 0 to 5 for both groups). There were no differences in patient satisfaction.</LI>
<LI>
<LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> reported 34 women (67%) in the Estring group and one (2%) in the control group were free of vaginal mucosal atrophy at the end of the treatment period.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vaginal oestrogens versus antibiotics</HEADING>
<P>Two studies used different mode of administration. <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> used a vaginal pessary and <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> used vaginal cream.</P>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of women with UTIs at the end of the treatment period</HEADING>
<P>The pooled results went in different directions and had significant heterogeneity. We have shown these results without the summary estimate.<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> (171 participants) reported significantly less UTIs in the antibiotic group compared to the oestrogen group (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>
<U>.1</U>: RR 1.30, 95% CI 1.01 to 1.68).</LI>
<LI>
<LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> (42 women) reported significantly less UTIs in the oestrogen group compared the antibiotic group after three months (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>
<U>.1</U>: RR 0.09, 95% CI 0.02 to 0.36). Two months after stopping treatment there was no significant difference in the number women with RUTIs (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>
<U>.2</U>: RR 0.56, 95% CI 0.09 to 3.55).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vaginal pH</HEADING>
<P>There was no statistical difference in vaginal pH between vaginal oestrogens and antibiotics (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (2 studies, 213 women: MD -1.69, 95% CI -4.24 to 0.85; I² = 99.3%), however there was very significant heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of women Lactobacillus positive</HEADING>
<P>There was no statistical difference in the number of women <I>Lactobacillus</I> positive between vaginal oestrogens and antibiotics (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (2 studies, 213 women): RR 4.02, 95% CI 0.25 to 65.06; I² = 75.1%). There was significant heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>
<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>
</P>
<UL>
<LI>
<LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> reported that in the oestrogen group five reported burning, two reported itching. Doses were decreased and three dropped out of the study. There were no reported side effects for the antibiotic group.</LI>
<LI>In <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> the adverse events were more frequent in the vaginal estrogens group, 36% for all adverse events and 16% for drug-related adverse events. In those women receiving oestriol the adverse events were itching, burning, vaginal discharge and metrorrhagia.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-12 16:26:40 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="2">Oral oestrogens versus placebo</HEADING>
<P>Oral oestrogens did not reduce the occurrence of RUTI or the number of postmenopausal women who were <I>Lactobacillus </I>positives<I>.</I> There was a significant decrease in vagina pH and significantly more women reported adverse events (breast tenderness, mild vaginal bleeding and spotting) in the group treated with oral oestrogens.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Vaginal oestrogens versus placebo</HEADING>
<P>There was a reduction on the number of UTIs in the vaginal oestrogens group in two studies. The two studies used different type of application method (<LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK> used topical vaginal cream and <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK> used releasing silicone vaginal ring (Estring) (2 mg oestriol) that it is likely to explain the heterogeneity in the pool analysis. Both trials have a reduction in the proportion of UTIs. The RR for <LINK REF="STD-Raz-1993" TYPE="STUDY">Raz 1993</LINK>, was 0.25 (95% CI 0.13 to 0.50) and in <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>, the RR was 0.64 (95% CI 0.47 to 0.86).</P>
<P>
<B>Vaginal oestrogens versus antibiotics<I>
<BR/>
</I>
</B>When pooling the results from the two studies that compared antibiotics and vaginal oestrogens, the differences in magnitude and direction of effects and the subsequent heterogeneity while pooling these two studies should be noted. One possible explanation is the use different types of vaginal oestrogens, <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> used a vaginal pessary and <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> vaginal cream. <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> discussed in his paper the small effect of oestrogens compared to nitrofurantoin and the paper suggest that the use of vaginal pessaries could have been less effective than the use of cream. It is seems that the oestrogens administration form may have had an impact on its effect on the vaginal mucosa. It is of notice the high number of infections under the antibiotics arm in the <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK> study. It is unclear the reason for this high number of infections in this group.</P>
<P>Evidence from two small studies shows that in postmenopausal women with RUTI, vaginal oestrogens reduce the number of UTIs. However the true magnitude of the effect is difficult to assess as the two studies used different type of vaginal oestrogens and different type of comparators. The significant heterogeneity seen in this comparison means it is not appropriate to pool these data.<BR/>
<BR/>The type of vaginal oestrogens to use is unclear; while cream seems more effective than vaginal ring, vaginal cream could be more difficult to apply for certain women and acceptability is lower compared to vaginal ring as it has to be applied every day to maintain the effect (<LINK REF="REF-Suckling-2006" TYPE="REFERENCE">Suckling 2006</LINK>). Vaginal ring on the other hand is more expensive and requires a trained doctor to place correctly. The role for vaginal pessaries is unclear. In the study by <LINK REF="STD-Raz-2003" TYPE="STUDY">Raz 2003</LINK> they were not effective in reducing the pH no increasing the presence of <I>Lactobacillus</I> or decreasing UTIs. Vaginal creams are possibly more suitable for outpatients and vaginal rings or pessaries could be used in nursing homes residents. Adverse events did occur more frequently in women receiving oestrogens comparing to placebo, no treatment or antibiotic. This issue must be discussed and anticipated with any potential patient as it may affect adherence to treatment. The effect of vaginal oestrogens on the reduction of UTIs could take at least 12 weeks (evaluating the time until recurrence or the time taken for the vaginal pH to decrease <LINK REF="STD-Eriksen-1999" TYPE="STUDY">Eriksen 1999</LINK>) and women should also be advised about this to avoid discontinuation of the treatment.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-14 08:34:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>In postmenopausal women with RUTI associated with a lack of oestrogens and signs and significant symptoms of vaginal atrophy, vaginal oestrogens are a potentially valid intervention. However, women should be advised that the evidence is based on only a few small studies.</LI>
<LI>The type of oestrogens to use is less clear. Vaginal rings need to be changed periodically and have to be placed by an experienced doctor, however they could be an option in women who have difficulties in applying a cream or used in nursing home residents.</LI>
<LI>Vaginal creams are a cheaper and possibly a more efficient option but women should be advised about adverse events (itching and burning, occasionally spotting).</LI>
<LI>The studies comparing vaginal oestrogens to antibiotics were inconclusive due to the significant heterogeneity between the two studies.</LI>
</UL>
<P> </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-14 08:35:01 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Future research should focus first in confirm the results of these small studies. They will need to evaluate which type of vaginal delivery is the best option and the outcomes should include cost, patient satisfaction and duration of treatment.</LI>
<LI>Is not clear how long treatment should be given, what is the best treatment schedule and what would be the long-term adverse consequences of sustaining this intervention for more than 8 months.</LI>
<LI>Studies comparing antibiotics plus vaginal oestrogens and vaginal oestrogens and cranberry juice should be encouraged in addition to studies in different populations (e.g. outpatients and nursing home residents or geriatric population).</LI>
</UL>
<P> </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr Shijun Zhou from the UCD School of Public Health and Cheen Werne Ng translated the Chinese paper. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None declared.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CP - Screen search results, select studies, assess quality, data extraction, data analysis and writing the final version of the review.<BR/>CWN - Search and retrieve relevant articles, did data extraction and entered into RevMan. <BR/>MA - Data extraction and quality assessments and collaborated in the final version of the review. <BR/>RM - Collaborated preparing the discussion and revising the review.<BR/>XA - Prepared the protocol and revised the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2001" NAME="Brown 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B</AU>
<TI>Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>6</NO>
<PG>1045-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11755552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cardozo-1998" NAME="Cardozo 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Cardozo L. Benness C. Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] British Journal of Obstetrics &amp;amp; Gynaecology. 105(4):403-7, 1998 Apr. UI: 9609266&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cardozo L, Benness C, Abbott D</AU>
<TI>Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women</TI>
<SO>British Journal of Obstetrics &amp; Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>4</NO>
<PG>403-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9609266"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksen-1999" NAME="Eriksen 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] American Journal of Obstetrics &amp;amp; Gynecology. 180(5):1072-9, 1999 May. UI: 10329858&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eriksen B</AU>
<TI>A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>1999</YR>
<VL>180</VL>
<NO>5</NO>
<PG>1072-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10329858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirkengen-1992" NAME="Kirkengen 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kirkengen AL. Andersen P. Gjersoe E. Johannessen GR. Johnsen N. Bodd E. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. [Clinical Trial. Journal Article. Randomized Controlled Trial] Scandinavian Journal of Primary Health Care. 10(2):139-42, 1992 Jun. UI: 1641524&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirkengen AL, Andersen P, Gjersoe E, Johannessen GR, Johnsen N, Bodd E</AU>
<TI>Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women</TI>
<SO>Scandinavian Journal of Primary Health Care</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>2</NO>
<PG>139-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1641524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjaergaard-1990" NAME="Kjaergaard 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Kjaergaard B. Walter S. Knudsen Aa. Johansen B. Barlebo H. Treatment with low-dose vaginal oestradiol in post-menopausal women. A double-blind controlled investigation. [Journal: Article] Ugeskrift for Laeger. Vol. 152(10)(pp 658-659), 1990. AN: 1990071458&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergaard B, Walter S, Knudsen A, Johansen B, Barlebo H</AU>
<TI>Treatment with low-dose vaginal oestradiol in post menopausal women. A double-blind controlled investigation</TI>
<TO>Behandling med lavdosis vaginal ostradiol hos postmenopausale kvinder</TO>
<SO>Ugeskr Laeger</SO>
<YR>1990</YR>
<VL>152</VL>
<NO>10</NO>
<PG>658-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 1990071458"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouslander-2001" NAME="Ouslander 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Ouslander JG. Greendale GA. Uman G. Lee C. Paul W. Schnelle J. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, U.S. Gov't, Non-P.H.S.. Research Support, U.S. Gov't, P.H.S.] Journal of the American Geriatrics Society. 49(6):803-7, 2001 Jun. UI: 11454122&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnelle J</AU>
<TI>Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>6</NO>
<PG>803-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11454122"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-1993" NAME="Raz 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Raz R. Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] New England Journal of Medicine. 329(11):753-6, 1993 Sep 9. UI: 8350884&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Stamm WE</AU>
<TI>A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>11</NO>
<PG>753-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8350884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-2003" NAME="Raz 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Raz R. Colodner R. Rohana Y. Battino S. Rottensterich E. Wasser I. Stamm W. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Clinical Infectious Diseases. 36(11):1362-8, 2003 Jun 1. UI: 12766829&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I et al</AU>
<TI>Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>11</NO>
<PG>1362-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12766829"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" NAME="Xu 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Xu R. Wu Y. Hu Y. [Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women]. [Chinese] [English Abstract. Journal Article] Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp;amp; Gynecology]. 36(9):531-3, 2001 Sep. UI: 11769665&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu R, Wu Y, Hu Y</AU>
<TI>Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women</TI>
<SO>Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp; Gynecology]</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>9</NO>
<PG>531-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11769665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayton-1996" NAME="Ayton 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Ayton RA. Darling GM. Murkies AL. Farrell EA. Weisberg E. Selinus I. Fraser ID. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. [Clinical Trial. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] British Journal of Obstetrics &amp;amp; Gynaecology. 103(4):351-8, 1996 Apr. UI: 8605133&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I et al</AU>
<TI>A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy</TI>
<SO>British Journal of Obstetrics &amp; Gynaecology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>4</NO>
<PG>351-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8605133"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brandberg-1987" NAME="Brandberg 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Brandberg A. Mellstrom D. Samsioe G. Low dose oral estriol treatment in elderly women with urogenital infections. [Journal Article] Acta Obstetricia et Gynecologica Scandinavica - Supplement. 140:33-8, 1987. &lt;br&gt;UI: 3475935&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brandberg A, Mellstrom D, Samsioe G</AU>
<TI>Low dose oral estriol treatment in elderly women with urogenital infections</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica - Supplement</SO>
<YR>1987</YR>
<VL>140</VL>
<PG>33-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3475935"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chompootaweep-1998" NAME="Chompootaweep 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Chompootaweep S. Nunthapisud P. Trivijitsilp P. Sentrakul P. Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Clinical Pharmacology &amp;amp; Therapeutics. 64(2):204-10, 1998 Aug. UI: 9728901&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N</AU>
<TI>The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1998</YR>
<VL>64</VL>
<NO>2</NO>
<PG>204-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9728901"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksson-1996" NAME="Henriksson 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Henriksson L. Stjernquist M. Boquist L. Cedergren I. Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] American Journal of Obstetrics &amp;amp; Gynecology. 174(1 Pt 1):85-92, 1996 Jan. &lt;br&gt;UI: 8572039&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I</AU>
<TI>A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>1 Pt 1</NO>
<PG>85-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8572039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marx-2004" NAME="Marx 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Marx P. Schade G. Wilbourn S. Blank S. Moyer DL. Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Maturitas. 47(1):47-54, 2004 Jan 20. UI: 14706765&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marx P, Schade G, Wilbourn S, Blank S, Moyer D, Nett R</AU>
<TI>Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis</TI>
<SO>Maturitas</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14706765"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molander-1990" NAME="Molander 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Molander U. Milsom I. Ekelund P. Mellstrom D. Eriksson O. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. [Clinical Trial. Controlled Clinical Trial. Journal Article. Randomized Controlled Trial] Maturitas. 12(2):113-20, 1990 Jun. UI: 2255263&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Molander U, Milsom I, Ekelund P, Mellstrom D, Eriksson O</AU>
<TI>Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause</TI>
<SO>Maturitas</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>2</NO>
<PG>113-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2255263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Notelovitz-1995" NAME="Notelovitz 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. [Clinical Trial. Journal Article. Randomized Controlled Trial] Maturitas. 22 Suppl:S31-3, 1995 Dec. UI: 8775774&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Notelovitz M</AU>
<TI>Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration</TI>
<SO>Maturitas</SO>
<YR>1995</YR>
<VL>22 Suppl</VL>
<PG>S31-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8775774"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orlander-1992" NAME="Orlander 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Orlander JD. Jick SS. Dean AD. Jick H. Urinary tract infections and estrogen use in older women. [Journal Article. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] Journal of the American Geriatrics Society. 40(8):817-20, 1992 Aug. UI: 1634725&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orlander JD, Jick SS, Dean AD, Jick H</AU>
<TI>Urinary tract infections and estrogen use in older women</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1992</YR>
<VL>40</VL>
<NO>8</NO>
<PG>817-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1634725"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Albert-2004" MODIFIED="2008-05-12 16:31:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Albert 2004" TYPE="COCHRANE_REVIEW">
<AU>Albert X, Huertas I, Pereiró I, Sanfélix J, Gosalbes V, Perrotta C</AU>
<TI>Antibiotics for preventing recurrent urinary tract infection in non-pregnant women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-12 16:31:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-12 16:31:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD001209.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-1999" NAME="Brown 1999" TYPE="JOURNAL_ARTICLE">
<AU>Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF</AU>
<TI>Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart &amp; Estrogen/Progestin Replacement Study (HERS) Research Group</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>1</NO>
<PG>66-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10389720"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Foxman-2000" NAME="Foxman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Foxman B, Barlow R, D'Arcy H, Guillespie B, Sobel JD</AU>
<TI>Urinary tract infection: self reported incidence and associated costs</TI>
<SO>Annals of Epidemiology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>8</NO>
<PG>509-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11118930"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Foxman-2001" NAME="Foxman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R et al</AU>
<TI>Urinary tract infection among women aged 40 to 65: Behavioral and sexual risk factors</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>7</NO>
<PG>710-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11438412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hu-2004" NAME="Hu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hu KK, Boyko EJ, Scholes D, Normand E, Chen CL, Grafton J et al</AU>
<TI>Risk factors for urinary tract infections in postmenopausal women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>9</NO>
<PG>989-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15136308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Iosif-1981" NAME="Iosif 1981" TYPE="JOURNAL_ARTICLE">
<AU>Iosif CS, Batra S, Ek A, Astedt B</AU>
<TI>Estrogen receptors in the human female lower urinary tract</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>1981</YR>
<VL>141</VL>
<NO>7</NO>
<PG>817-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7198384"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jepson-2004" MODIFIED="2008-05-12 16:31:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jepson 2004" TYPE="COCHRANE_REVIEW">
<AU>Jepson RG, Mihaljevic L, Craig J</AU>
<TI>Cranberries for preventing urinary tract infections</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-12 16:31:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-12 16:31:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD001321.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Master-List-2007" NAME="Master List 2007" TYPE="OTHER">
<AU>United States Cochrane Center</AU>
<TI>Master list of journals being searched</TI>
<SO>http://apps1.jhsph.edu/cochrane/masterlist.asp</SO>
<YR>(accessed May 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moehrer-2004" MODIFIED="2008-05-12 16:31:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Moehrer 2004" TYPE="COCHRANE_REVIEW">
<AU>Moehrer B, Hextall A, Jackson S</AU>
<TI>Oestrogens for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-12 16:31:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-12 16:31:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="0.1002/14651858.CD001405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raz-2000" NAME="Raz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E et al</AU>
<TI>Recurrent urinary tract infections in postmenopausal women</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>1</NO>
<PG>152-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10619744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raz-2001" NAME="Raz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Raz R</AU>
<TI>Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183 Suppl</VL>
<NO>1</NO>
<PG>74-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11171020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2003" NAME="Robinson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Robinson D, Cardozo LD</AU>
<TI>The role of estrogens in female lower urinary tract dysfunction</TI>
<SO>Urology</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>4 Suppl 1</NO>
<PG>45-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14550837"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Suckling-2006" MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Suckling 2006" TYPE="COCHRANE_REVIEW">
<AU>Suckling J, Lethaby A, Kennedy R</AU>
<TI>Local oestrogen for vaginal atrophy in postmenopausal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-12 16:32:18 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD001500.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-12 16:27:26 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-05-12 16:27:26 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Brown-2001">
<CHAR_METHODS>
<P>Randomised, double-blinded controlled trial.<BR/>20 clinical centres in the US.<BR/>Jan 1993 and Sep 1994.<BR/>Follow-up: Mean of 4.1 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 2763 postmenopausal women.<BR/>Age: &lt; 80 years old.<BR/>Coronary heart disease and intact uterus.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>0.625 mg of oral conjugated oestrogen plus 2.5 mg of medroxyprogesterone acetate.</P>
<P>CONTROL GROUP<BR/>Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Proportion with 2 or more UTIs during the 1st, 2nd, 3rd and 4th year of treatment (dichotomous).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Definition of RUTI: two or more UTIs.<BR/>Logistic regression to examine the predictors of UTIs. Data not collected for this outcome (secondary analysis).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cardozo-1998">
<CHAR_METHODS>
<P>Double-blind, randomised, parallel group, placebo-controlled trial.<BR/>Randomisation, blinding OK, allocation seems to follow randomisation.<BR/>King's College Hospital, St Pancras Hospital and Dulwich Hospital, London (UK).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Recurrent UTI.<BR/>Number: 72 postmenopausal women.<BR/>Age: &gt; 60 years (mean 73.2 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Oral oestriol (3 mg/d) for 6 months, followed for a further 6 months after treatment.</P>
<P>CONTROL GROUP<BR/>Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Percentage of women remaining infection-free (dichotomous).<BR/>2. Breast tenderness (dichotomous).<BR/>3. Vaginal bleeding (dichotomous).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Definition of RUTI: at least UTI.<BR/>Twenty-two women were unable to complete the trial. Reasons for early discontinuation in the oestriol group (n = 13) were major protocol violation (n = 4); hospital admission (n = 2); bleeding (n = 2); cerebrovascular accident (n = 2); poor compliance; adverse experiences; and depression. Early discontinuation reasons in the placebo group (n = 9) included femur fracture (n = 2); poor compliance; major protocol violation; septicaemia; cerebrovascular accident; left arm paresis; adverse experiences and general decline in health.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-12 16:27:26 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Eriksen-1999">
<CHAR_METHODS>
<P>Multi-centred (15), randomised, open, parallel group study.<BR/>Country: Norway.<BR/>Time frame: 15 October 1993 to 5 June 1996.<BR/>Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-12 16:27:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Number: 108 women.<BR/>Age: &#8805; 2 years after spontaneous or surgical menopause.<BR/>UTIs: &#8805; 3 treated during previous 12 months and had normal urine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Estradiol-releasing silicone vaginal ring (Estring) (2 mg oestriol) was carried vaginally for 12 weeks.</P>
<P>CONTROL GROUP<BR/>Untreated controlled group.</P>
<P>Duration of treatment: 36 weeks for Estring group, and until first recurrence for the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Proportion of women with recurrent UTI (dichotomous).<BR/>2. Proportion of women remaining free of UTI (dichotomous).<BR/>3. Vaginal mucosal atrophy (dichotomous).<BR/>4. Vaginal pH (continuous).<BR/>5. Vaginal bleeding (dichotomous).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality is lower than the others.<BR/>"Fourteen of the 108 subjects (9 subjects treated with the vaginal ring and 5 with no oestrogen treatment) were excluded from the per-protocol analysis of time to first recurrence. In addition, 3 subjects, all from the Estring group, were excluded from the per-protocol analysis for secondary variables. Five subjects (9%) withdrew from the ring group and 1 subject (2%) withdrew from the control group before completion of the 36-week study period or before first recurrence (control group). The reason for withdrawal was "local discomfort" (3 subjects in the Estring group) or "subject's own wish" (2 subjects in the Estring group and 1 subject in the control group)".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kirkengen-1992">
<CHAR_METHODS>
<P>Randomised, double-blind, group-comparative, placebo-controlled trial.<BR/>Block randomisation.<BR/>In-patients at the Red Cross Clinic and patients being treated by general practitioners in Oslo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 40 postmenopausal women.<BR/>Age: median 78 years (66-91).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Single daily 3 mg oral oestriol every morning during the first 4 weeks and 1 mg/d during the last 8 weeks of the treatment period.</P>
<P>CONTROL GROUP<BR/>Placebo in the same schedule as treatment group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Proportion of women with recurrent UTI (dichotomous).<BR/>2. Vaginal pH (continuous).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Definition of RUTI: at least one episode with a repeat infection within two weeks or at least three episodes during the previous year.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kjaergaard-1990">
<CHAR_METHODS>
<P>Randomised double-blind, control trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 21 postmenopausal women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Vaginal estradiol.</P>
<P>CONTROL GROUP<BR/>Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Median of UTI at the end of the study period.<BR/>2. Patient satisfaction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ouslander-2001">
<CHAR_METHODS>
<P>Randomised placebo-controlled trial.<BR/>5 community nursing homes in USA.<BR/>Allocation concealment adequate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 32 incontinent female residents.<BR/>Age: average 88 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Oral oestrogen (0.625 mg/d) combined with progesterone (2.5 mg/d) for 6 months.</P>
<P>CONTROL GROUP<BR/>Placebo for 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Percentage of vaginal superficial cells (dichotomous).<BR/>2. Vaginal parabasal cells (continuous).<BR/>3. Vaginal pH (continuous).<BR/>4. Bacteriuria and pyuria (dichotomous).<BR/>5. Presence of lactobacillus (dichotomous).<BR/>6. Breast discomfort (dichotomous).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Definition of RUTI: prevalence of bacteriuria.<BR/>Three (9%) dropped out before the 3-month examination (two active, one placebo), leaving 29 subjects who had 3-month measures (13 active and 16 placebo; 91% of those enrolled). An additional eight (25%) dropped out before the 6-month examination (four active, four placebo), leaving 21 subjects who had 6-month measures (nine active and 12 placebo; 66% of those enrolled). Reasons for dropping out were primarily various acute illnesses (which resulted in two deaths)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raz-1993">
<CHAR_METHODS>
<P>Randomised, double-blind, placebo-controlled trial.<BR/>Infectious Diseases Clinic, Central Emek Hospital, Afula, Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 93 postmenopausal women.<BR/>History of 3 or more microbiologically confirmed symptomatic episodes or UTI during the previous year.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Topically applied intravaginal oestriol cream of 0.5 mg each night for 2 weeks followed by twice-weekly applications for 8 months.</P>
<P>CONTROL GROUP<BR/>Placebo applied in a same manner as treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Incidence of UTI (dichotomous).<BR/>2. Proportion of patients remaining free of UTI (dichotomous).<BR/>3. Presence of lactobacillus (dichotomous).<BR/>4. Vaginal pH (continuous).<BR/>5. Number of episodes of UTI/patient/year) (continuous).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reasons for early withdrawal from the study: side effects in 10 women in the oestriol group and 4 in the placebo group; lack of compliance with follow-up in 3 and 5 women, respectively; death due to myocardial infarction in 1 oestriol-treated patient; and failure to respond to topical prophylaxis necessitating systemic antimicrobial prophylaxis for recurrent infections in 10 women in the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raz-2003">
<CHAR_METHODS>
<P>Double-blind, double dummy, randomised trial.<BR/>Outpatient clinics (3) in northern Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 171 postmenopausal women.<BR/>History of recurrent UTI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Oestriol-containing vaginal pessary.<BR/>Daily for 2 weeks, and then once every 2 weeks for 9 months together with oral placebo capsules each night during the same period. </P>
<P>CONTROL GROUP<BR/>Nitrofurantoin macrocrystal (NM).<BR/>A capsule of NM nightly for 9 months together with a placebo vaginal pessary daily for 2 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Number of UTI episodes/patient/(continuous).<BR/>2. Proportion of women who remained free of UTI (dichotomous).<BR/>3. Percentage of superficial cells (dichotomous).<BR/>4. Lactobacillus colonisation (dichotomous).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Twenty-seven patients in the oestriol group and 23 in the NM group dropped out.<BR/>Reasons for dropout included adverse events (9 patients in the oestriol group and 14 in the NM group), lack of compliance with the treatment regimen (13 and 6, respectively), and intermittent illness (3 and 2, respectively)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Xu-2001">
<CHAR_METHODS>
<P>Randomised control trial.<BR/>Gynaecological units.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 45 postmenopausal women.<BR/>History of recurrent UTI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP<BR/>Vaginal estrogens (intravaginal premarin cream) for 3 months.<BR/>Number: 30.</P>
<P>CONTROL GROUP<BR/>Oral ofloxacin 600 mg/d for 3 months.<BR/>Number: 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. UTI.<BR/>2. Adverse events.<BR/>3. Vaginal pH.<BR/>4. UTI two months after finishing the study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ayton-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes for urogenital atrophy in postmenopausal women, not about the treatment for recurrent UTI in postmenopausal women.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brandberg-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>The quality of this clinical trial was low.<BR/>The primary outcomes were not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chompootaweep-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes for vaginal atrophy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henriksson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The primary outcomes were not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marx-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Main outcomes were vaginal atrophy.<BR/>Participants did not meet inclusion criteria for this systematic review (no previous history of UTI).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Molander-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Main outcomes were related to vaginal atrophy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Notelovitz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants did not meet the inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orlander-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brown-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cardozo-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eriksen-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kirkengen-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kjaergaard-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ouslander-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Raz-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Raz-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xu-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-12 16:29:10 +1000" MODIFIED_BY="Narelle S Willis"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-12 16:33:04 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-12 16:33:04 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Oral oestrogens versus placebo</NAME>
<DICH_OUTCOME CHI2="1.2752686098001562" CI_END="1.3266823262483287" CI_START="0.8843158707835272" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.083146452050417" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.12276694360761886" LOG_CI_START="-0.05339258064826386" LOG_EFFECT_SIZE="0.0346871814796775" METHOD="MH" MODIFIED="2008-05-12 16:33:00 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7350141019758015" P_Q="0.0" P_Z="0.4401947932941198" Q="0.0" RANDOM="YES" SCALE="56.49309993574531" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1389" TOTAL_2="1409" WEIGHT="100.00000000000001" Z="0.7718643282280819">
<NAME>UTI at the end of the treatment period</NAME>
<GROUP_LABEL_1>Oral oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.410699537476376" CI_START="0.8813186126562117" EFFECT_SIZE="1.1150227617602428" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="120" LOG_CI_END="0.1494345239518095" LOG_CI_START="-0.0548670578722878" LOG_EFFECT_SIZE="0.04728373303976087" ORDER="30656" O_E="0.0" SE="0.12000776047261497" STUDY_ID="STD-Brown-2001" TOTAL_1="1318" TOTAL_2="1336" VAR="0.014401862573652528" WEIGHT="74.34791591368248"/>
<DICH_DATA CI_END="1.6548556709539741" CI_START="0.6732898526563929" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.21876012255791377" LOG_CI_START="-0.171797930858868" LOG_EFFECT_SIZE="0.023481095849522904" ORDER="30657" O_E="0.0" SE="0.22941573387056177" STUDY_ID="STD-Cardozo-1998" TOTAL_1="36" TOTAL_2="36" VAR="0.05263157894736842" WEIGHT="20.344220884900253"/>
<DICH_DATA CI_END="2.938902847851195" CI_START="0.03780700379134716" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46818522971347326" LOG_CI_START="-1.4224277391527982" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="30658" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Kirkengen-1992" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="0.8681744332105372"/>
<DICH_DATA CI_END="2.4728576680132095" CI_START="0.36070628737747895" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39319912009143765" LOG_CI_START="-0.442846287541502" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="30659" O_E="0.0" SE="0.4910972109351012" STUDY_ID="STD-Ouslander-2001" TOTAL_1="15" TOTAL_2="17" VAR="0.24117647058823533" WEIGHT="4.43968876820673"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5684036766254992" CI_START="-1.4315963233745008" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-05-12 16:33:04 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.593569911549227E-6" Q="0.0" RANDOM="YES" SCALE="2.1156595036266372" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="4.541197128872138">
<NAME>Vaginal pH</NAME>
<GROUP_LABEL_1>Oral oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.44737513806514084" CI_START="-1.5526248619348593" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.5" ORDER="30660" SD_1="0.61" SD_2="0.93" SE="0.28195664119029407" STUDY_ID="STD-Kirkengen-1992" TOTAL_1="13" TOTAL_2="17" WEIGHT="60.99505594895661"/>
<CONT_DATA CI_END="-0.30893657734311086" CI_START="-1.6910634226568892" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.5" ORDER="30661" SD_1="1.0" SD_2="0.99" SE="0.3525898578279546" STUDY_ID="STD-Ouslander-2001" TOTAL_1="15" TOTAL_2="17" WEIGHT="39.00494405104338"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Lactobacillus positive</NAME>
<GROUP_LABEL_1>Oral oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="173.83065592861834" CI_START="0.5897442223430195" EFFECT_SIZE="10.125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2401263689285154" LOG_CI_START="-0.22933630515510303" LOG_EFFECT_SIZE="1.0053950318867062" ORDER="30662" O_E="0.0" SE="1.450574598794101" STUDY_ID="STD-Ouslander-2001" TOTAL_1="15" TOTAL_2="17" VAR="2.104166666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004909941048033208" CI_END="18.757280277078983" CI_START="1.3946879819237452" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.1147388375182326" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.2731698678231997" LOG_CI_START="0.14447705858777976" LOG_EFFECT_SIZE="0.7088234632054898" METHOD="MH" NO="4" P_CHI2="0.9441371713384844" P_Q="0.0" P_Z="0.01382687225102935" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="53" WEIGHT="100.0" Z="2.4617299727829525">
<NAME>All adverse events</NAME>
<GROUP_LABEL_1>Oral oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Less with placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.234480967297166" CI_START="1.1773304013647439" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3270416500314959" LOG_CI_START="0.07089835864054149" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="30663" O_E="0.0" SE="0.7378647873726218" STUDY_ID="STD-Cardozo-1998" TOTAL_1="36" TOTAL_2="36" VAR="0.5444444444444444" WEIGHT="80.73710073710075"/>
<DICH_DATA CI_END="108.63171039081135" CI_START="0.29126509088525177" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0359566174952812" LOG_CI_START="-0.5357115639284808" LOG_EFFECT_SIZE="0.7501225267834001" ORDER="30664" O_E="0.0" SE="1.510610619731122" STUDY_ID="STD-Ouslander-2001" TOTAL_1="15" TOTAL_2="17" VAR="2.2819444444444446" WEIGHT="19.26289926289926"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Vaginal oestrogens versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="103" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>UTI at the end of the treatment period</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="27" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="0.5007123725973622" CI_START="0.12967642383648664" EFFECT_SIZE="0.2548148148148148" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.30041167705650734" LOG_CI_START="-0.8871389747904447" LOG_EFFECT_SIZE="-0.5937753259234759" ORDER="30665" O_E="0.0" SE="0.34464651903587923" STUDY_ID="STD-Raz-1993" TOTAL_1="50" TOTAL_2="43" VAR="0.11878122308354867" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="44" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>No treatment</NAME>
<DICH_DATA CI_END="0.8556289962278246" CI_START="0.4739257666222384" EFFECT_SIZE="0.6367924528301887" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="44" LOG_CI_END="-0.06771450613842597" LOG_CI_START="-0.3242896787290646" LOG_EFFECT_SIZE="-0.1960020924337453" ORDER="30666" O_E="0.0" SE="0.15071352644732885" STUDY_ID="STD-Eriksen-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.022714567054189692" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Vaginal pH</NAME>
<GROUP_LABEL_1>Oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8410810497564356" CI_START="-3.1589189502435637" EFFECT_SIZE="-2.4999999999999996" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="6.1" ORDER="30667" SD_1="1.0" SD_2="2.0" SE="0.33618931543693276" STUDY_ID="STD-Raz-1993" TOTAL_1="50" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Lactobacillus positive</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="621.5991413814745" CI_START="2.4248206531243444" EFFECT_SIZE="38.8235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="2.793510405899767" LOG_CI_START="0.38467962242742226" LOG_EFFECT_SIZE="1.5890950141635947" ORDER="30668" O_E="0.0" SE="1.41495912611634" STUDY_ID="STD-Raz-1993" TOTAL_1="50" TOTAL_2="43" VAR="2.0021093285799165" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.078433101928664" CI_END="33.5305096795004" CI_START="0.6652269216768948" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.722859063782379" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" I2="67.51594181554599" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.525440154959158" LOG_CI_START="-0.1770301832361474" LOG_EFFECT_SIZE="0.6742049858615053" METHOD="MH" NO="4" P_CHI2="0.07933717952103891" P_Q="0.0" P_Z="0.12057777660795832" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.3937172338229313" TOTALS="YES" TOTAL_1="103" TOTAL_2="98" WEIGHT="100.0" Z="1.5523530258819644">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Less with placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.366080167113543" CI_START="0.726114010294642" DF="0.0" EFFECT_SIZE="2.15" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.8038721033261127" LOG_CI_START="-0.13899518349490214" LOG_EFFECT_SIZE="0.33243845991560533" NO="1" P_CHI2="1.0" P_Z="0.1669416692828587" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="43" WEIGHT="58.812214021143355" Z="1.3820978150750847">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="6.366080167113543" CI_START="0.726114010294642" EFFECT_SIZE="2.15" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8038721033261127" LOG_CI_START="-0.13899518349490214" LOG_EFFECT_SIZE="0.33243845991560533" ORDER="30669" O_E="0.0" SE="0.5538449115470067" STUDY_ID="STD-Raz-1993" TOTAL_1="50" TOTAL_2="43" VAR="0.3067441860465116" WEIGHT="58.812214021143355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="106.64105092596876" CI_START="1.9792711519722823" DF="0.0" EFFECT_SIZE="14.528301886792452" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="2.027924416311093" LOG_CI_START="0.29650529483229193" LOG_EFFECT_SIZE="1.1622148555716927" NO="2" P_CHI2="1.0" P_Z="0.008507114831135488" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="41.187785978856645" Z="2.6312511291574388">
<NAME>No treatment</NAME>
<DICH_DATA CI_END="106.64105092596876" CI_START="1.9792711519722823" EFFECT_SIZE="14.528301886792454" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="2.027924416311093" LOG_CI_START="0.29650529483229193" LOG_EFFECT_SIZE="1.162214855571693" ORDER="30670" O_E="0.0" SE="1.0170441626195252" STUDY_ID="STD-Eriksen-1999" TOTAL_1="53" TOTAL_2="55" VAR="1.0343788287184514" WEIGHT="41.187785978856645"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-12 16:32:44 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Vaginal oestrogens versus antibiotics</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="62" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-12 16:32:32 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="76.41139630306112" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="140" TOTAL_2="115" WEIGHT="0.0" Z="0.0">
<NAME>UTI</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="60" EVENTS_2="56" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="113" TOTAL_2="100" WEIGHT="0.0" Z="0.0">
<NAME>UTI at end of treatment period</NAME>
<DICH_DATA CI_END="1.676819285711204" CI_START="1.0122908767190502" EFFECT_SIZE="1.3028541226215644" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.2244862603118563" LOG_CI_START="0.005305322783093334" LOG_EFFECT_SIZE="0.11489579154747484" ORDER="30671" O_E="0.0" SE="0.12874796766753419" STUDY_ID="STD-Raz-2003" TOTAL_1="86" TOTAL_2="85" VAR="0.01657603917852043" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.3598142918442654" CI_START="0.0238272586646685" EFFECT_SIZE="0.09259259259259259" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.4439215904461916" LOG_CI_START="-1.6229259205277078" LOG_EFFECT_SIZE="-1.0334237554869496" ORDER="30672" O_E="0.0" SE="0.6925529796554409" STUDY_ID="STD-Xu-2001" TOTAL_1="27" TOTAL_2="15" VAR="0.47962962962962963" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>UTI - recurrence 2 months after treatment</NAME>
<DICH_DATA CI_END="3.5529157077996185" CI_START="0.08687005285013902" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5505849040635626" LOG_CI_START="-1.061129914270175" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="30673" O_E="0.0" SE="0.9467292624062575" STUDY_ID="STD-Xu-2001" TOTAL_1="27" TOTAL_2="15" VAR="0.8962962962962964" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="147.11402203036616" CI_END="0.8529437332570051" CI_START="-4.242924791870075" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6949905293065348" ESTIMABLE="YES" I2="99.32025514210088" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-05-12 16:32:44 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="-8.881784197001252E-16" P_Q="1.0" P_Z="0.192285225677887" Q="0.0" RANDOM="YES" SCALE="4.59645083531858" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.3570246238030097" TOTALS="YES" TOTAL_1="113" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="1.303848549151666">
<NAME>Vaginal pH</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotics</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.20448681487838022" CI_START="-0.5955131851216204" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="5.7" ORDER="30674" SD_1="0.6" SD_2="0.7" SE="0.09975345805525163" STUDY_ID="STD-Raz-2003" TOTAL_1="86" TOTAL_2="85" WEIGHT="50.19267194974866"/>
<CONT_DATA CI_END="-2.6281229806172632" CI_START="-3.3718770193827368" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="7.5" ORDER="30675" SD_1="0.3" SD_2="0.7" SE="0.18973665961010275" STUDY_ID="STD-Xu-2001" TOTAL_1="27" TOTAL_2="15" WEIGHT="49.807328050251336"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.020681283835279" CI_END="65.16624296706277" CI_START="0.2483996362899048" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.02334078240931" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="10" I2="75.12859315608044" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.8140226833140418" LOG_CI_START="-0.6048490443948253" LOG_EFFECT_SIZE="0.6045868194596081" METHOD="MH" NO="3" P_CHI2="0.04494563767096105" P_Q="0.0" P_Z="0.3271999151649554" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.1802726793818032" TOTALS="YES" TOTAL_1="113" TOTAL_2="100" WEIGHT="100.0" Z="0.9797695165843647">
<NAME>Lactobacillus positive</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.113184002045095" CI_START="0.7060227200375089" EFFECT_SIZE="1.4825581395348837" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.4932047900404529" LOG_CI_START="-0.1511813229876404" LOG_EFFECT_SIZE="0.17101173352640622" ORDER="30676" O_E="0.0" SE="0.3785155925554053" STUDY_ID="STD-Raz-2003" TOTAL_1="86" TOTAL_2="85" VAR="0.14327405380756958" WEIGHT="60.743399147531406"/>
<DICH_DATA CI_END="293.68714059656475" CI_START="1.210784496768849" EFFECT_SIZE="18.857142857142858" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.4678849308938653" LOG_CI_START="0.08306685148932079" LOG_EFFECT_SIZE="1.275475891191593" ORDER="30677" O_E="0.0" SE="1.4008539448821118" STUDY_ID="STD-Xu-2001" TOTAL_1="27" TOTAL_2="15" VAR="1.962391774891775" WEIGHT="39.2566008524686"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6710355793931443" CI_END="94.28760094337383" CI_START="1.7542308454728224" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.860879360311984" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.97445458567563" LOG_CI_START="0.24408674314534634" LOG_EFFECT_SIZE="1.1092706644104882" METHOD="MH" NO="4" P_CHI2="0.41269112022049803" P_Q="0.0" P_Z="0.0119739397738516" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="100" WEIGHT="100.0" Z="2.5129114144564597">
<NAME>Adverse events (burning, itching or vaginal bleeding)</NAME>
<GROUP_LABEL_1>Vaginal oestrogens</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="473.01633166532315" CI_START="1.737313751693497" EFFECT_SIZE="28.666666666666668" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6748761357265733" LOG_CI_START="0.2398782573212375" LOG_EFFECT_SIZE="1.4573771965239053" ORDER="30678" O_E="0.0" SE="1.4303298072091877" STUDY_ID="STD-Raz-2003" TOTAL_1="86" TOTAL_2="85" VAR="2.045843357391072" WEIGHT="50.49864169540085"/>
<DICH_DATA CI_END="96.35027995975328" CI_START="0.3345407044396898" EFFECT_SIZE="5.67741935483871" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9838529808990937" LOG_CI_START="-0.4755510329393393" LOG_EFFECT_SIZE="0.7541509739798772" ORDER="30679" O_E="0.0" SE="1.4446660919749077" STUDY_ID="STD-Xu-2001" TOTAL_1="30" TOTAL_2="15" VAR="2.0870601173020527" WEIGHT="49.50135830459915"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-12 16:28:59 +1000" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2008-05-12 16:28:59 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2008-05-12 16:28:25 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-12 16:28:59 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<P>#1 MeSH descriptor Urinary Tract Infections explode all trees in MeSH products<BR/>#2 urin* near infect* in All Fields in all products<BR/>#3 uti or utis in All Fields in all products<BR/>#4 bacteriuria in All Fields in all products<BR/>#5 pyuria in All Fields in all products<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Estrogens explode all trees in MeSH products<BR/>#8 MeSH descriptor Estrogen Replacement Therapy, this term only in MeSH products<BR/>#9 estrogen* in All Fields in all products<BR/>#10 oestrogen* in All Fields in all products<BR/>#11 ERT in All Fields in all products<BR/>#12 (#7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 (#6 AND #12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<P>1. exp urinary tract infections/<BR/>2. (urin$ adj3 infection$).tw.<BR/>3. uti$.tw.<BR/>4. bacteriuria$.tw.<BR/>5. pyuria.tw.<BR/>6. or/1-5<BR/>7. exp Estrogens/<BR/>8. Estrogen Replacement Therapy/<BR/>9. estrogen$.tw.<BR/>10. oestrogen$.tw.<BR/>11. ert.tw.<BR/>12. or/7-11</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<P>1. exp Urinary Tract Infection/<BR/>2. (urin$ adj3 infection$).tw.<BR/>3. uti$.tw.<BR/>4. exp BACTERIURIA/<BR/>5. bacteriuria$.tw.<BR/>6. exp PYURIA/<BR/>7. pyuria.tw.<BR/>8. or/1-7<BR/>9. Estrogen/<BR/>10. Estrogen Therapy/<BR/>11. estrogen$.tw.<BR/>12. oestrogen$.tw.<BR/>13. ert.tw.<BR/>14. or/9-13<BR/>15. 8 and 14</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>